ABEONA THERAPEUTICS INC. short interest in 2022
In 2022, ABEONA THERAPEUTICS INC.'s disclosed short interest ran from 1.45% of shares outstanding on 14 Jan 2022 to 5.98% on 30 Dec 2022, a change of +4.53 percentage points. The year's high was 12.18% on 31 Oct 2022 and its low 1.45% on 14 Jan 2022, averaging 4.60% across 20 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 4.58 days on 15 Dec 2022. Full history: ABEONA THERAPEUTICS INC..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2022 in figures
- Start of year
- 1.45% (14 Jan 2022)
- End of year
- 5.98% (30 Dec 2022)
- Change
- +4.53 pp
- High
- 12.18% (31 Oct 2022)
- Low
- 1.45% (14 Jan 2022)
- Average
- 4.60%
- Highest days to cover
- 4.58 (15 Dec 2022)
- SEC filings marked
- 8
Every report in 2022
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 14 Jan 2022 | 1.45% | 1.00 | |
| 28 Feb 2022 | 3.62% | 3.13 | |
| 15 Mar 2022 | 3.96% | 1.84 | |
| 31 Mar 2022 | 2.68% | 2.12 | 10-K filed, results (8-K) |
| 14 Apr 2022 | 3.16% | 1.89 | |
| 29 Apr 2022 | 2.74% | 2.98 | |
| 13 May 2022 | 2.98% | 1.56 | 10-Q filed, results (8-K) |
| 31 May 2022 | 2.93% | 3.81 | |
| 15 Jun 2022 | 3.44% | 3.49 | |
| 30 Jun 2022 | 3.18% | 2.29 | |
| 15 Aug 2022 | 4.42% | 1.00 | 10-Q filed, results (8-K) |
| 31 Aug 2022 | 3.28% | 1.82 | |
| 15 Sep 2022 | 2.98% | 1.99 | |
| 30 Sep 2022 | 4.28% | 2.90 | |
| 14 Oct 2022 | 10.21% | 1.00 | |
| 31 Oct 2022 | 12.18% | 1.80 | |
| 15 Nov 2022 | 6.23% | 1.21 | 10-Q filed, results (8-K) |
| 30 Nov 2022 | 5.98% | 4.48 | |
| 15 Dec 2022 | 6.31% | 4.58 | |
| 30 Dec 2022 | 5.98% | 2.54 |
See also: ABEONA THERAPEUTICS INC.'s full history · most shorted US stocks of 2022 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.